Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer

The Oncologist
Lawrence LeichmanHoward S Hochster

Abstract

Effective new agents for patients with colorectal cancer (CRC) with disease progression during standard therapy regimens are needed. We hypothesized that poly ADP ribose polymerase (PARP) inhibitor therapy in patients with CRC and inefficient tumor DNA repair mechanisms, such as those with high-level microsatellite instability (MSI-H), would result in synthetic lethality. This was an open-label phase II trial testing olaparib 400 mg p.o. b.i.d. for patients with disseminated, measurable CRC failing standard therapies with centrally confirmed tumor MSI status. The primary endpoint was the tumor response, assessed by RECIST, version 1.0. The secondary endpoints were safety/toxicity, progression-free survival (PFS), and overall survival (OS). Thirty-three patients (20 microsatellite stable [MSS], 13 MSI-H) were enrolled. The median age for all patients was 57 years and for MSS and MSI-H patients was 51 and 61 years, respectively. All patients received at least one 28-day cycle of olaparib. No patient had a complete or partial response. Nausea (48%), fatigue (36%), and vomiting (33%) were the most commonly reported treatment-related adverse events. The median PFS for all patients was 1.84 months. No statistically significant differ...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Feb 19, 2002·EMBO Reports·Giuseppe GianniniAlberto Gulino
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Aug 21, 2004·Carcinogenesis·Laura OttiniDomenico Palli
Nov 25, 2004·Progress in Biophysics and Molecular Biology·Paul A NguewaJosé M Pérez
Oct 24, 2008·The New England Journal of Medicine·Christos S KarapetisJohn R Zalcberg
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joann P PalmaCherrie K Donawho
Apr 24, 2010·The Journal of Molecular Diagnostics : JMD·Jonathan S L EarleStanley R Hamilton
Nov 3, 2012·Cancer Research·Junko MuraiYves Pommier
Jan 22, 2013·Cancer Chemotherapy and Pharmacology·Tetsuya TaguchiUNKNOWN Kinki Breast Cancer Study Group (KBCSG)
Aug 6, 2013·Human Molecular Genetics·Joshua A RegalDavid O Ferguson
Sep 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frank A SinicropeSteven R Alberts
Aug 21, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sabine VenderboschMiriam Koopman
Oct 31, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kim A ReissNilofer S Azad
Nov 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bella KaufmanSusan M Domchek
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Mar 11, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U A MatulonisR L Coleman

❮ Previous
Next ❯

Citations

Jun 18, 2016·Current Treatment Options in Oncology·Dionisia QuirogaMichael A Morse
Jul 28, 2016·Current Opinion in Oncology·Alexandra LearySoizick Mesnage
Feb 19, 2017·British Journal of Pharmacology·Nathan A BergerCsaba Szabo
Feb 28, 2018·CA: a Cancer Journal for Clinicians·Patrick M BolandC Richard Boland
Jan 23, 2019·International Journal of Cancer. Journal International Du Cancer·Tianjin YiXia Zhao
Feb 5, 2019·Molecular Oncology·Nicole M ReillyAlberto Bardelli
Sep 3, 2019·Expert Review of Gastroenterology & Hepatology·Irem GulerIbrahim Halil Sahin
Oct 19, 2019·Targeted Oncology·Esha SachdevMonica M Mita
Jan 14, 2017·World Journal of Gastroenterology : WJG·Francois GhiringhelliRomain Boidot
Dec 14, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sabrina ArenaAlberto Bardelli
Nov 18, 2020·Cancers·Eleonora MolinaroGiulia Rovesti
Jan 8, 2021·Journal of Experimental & Clinical Cancer Research : CR·Pietro Paolo VitielloErika Martinelli
Oct 31, 2017·Endocrinology and Metabolism Clinics of North America·Moray J Campbell, Donald L Trump
Jun 5, 2021·Journal of Cancer Research and Clinical Oncology·Marije E WeidemaYvonne M H Versleijen-Jonkers
Jul 2, 2021·Frontiers in Cell and Developmental Biology·Elena Navarro-Carrasco, Pedro A Lazo
Aug 28, 2021·Biomedicines·Abdullah AlhusainiNiamh Lynam-Lennon
Jun 9, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G MauriA Sartore-Bianchi
Sep 21, 2021·Frontiers in Cell and Developmental Biology·Ignacio Campillo-MarcosPedro A Lazo
Sep 2, 2021·Journal of the National Cancer Institute·Roberto MorettoChiara Cremolini

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.